References
- 1. Bolotov DD, Novikov AA, Bolevich S, Novikova NA, Yakovchenko AV. Influence of systemic inflammatory response to appearance of new foci of chronic inflammation. Ser J Exp Clin Res. 2020; 21 (1): 3-10.
- 2. Varga Z, Flammer AJ, Steiger P, Haberecker M, Ander-matt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234): 1417-18.
- 3. Md Insiat Islam Rabby. Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J Pharm Pharm Sci. 2020; 23(1): 58-64.
- 4. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-3.
- 5. Atri D, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. JACC Basic Transl Sci. 2020; 5(5): 518-36.
- 6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271-80.
- 7. Muus C, et al., Integrated analyses of single-cell atlases reveal age, gender, and smoking status associations with cell type-specific expression of mediators of SARSCoV-2 viral entry and highlights inflammatory programs in putative target cells. bioRxiv. 2020; doi: 10.1101/2020.04.19.049254.
- 8. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H. The emerging role of ACE2 in physiology and disease. J Pathol. 2007; 212(1): 1-11.
- 9. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203: 631-7.
- 10. Ferrario CM, Jessup J, Chappell MC et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111: 2605-2610.
- 11. Carly G, Ziegler K, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 2020. doi: 10.1016/j.cell.2020.04.035.
- 12. Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. The Vascular Endothelium and Human Diseases. Int J Biol Sci 2013; 9(10): 1057–1069.
- 13. Kade AK, Zanin SA, Gubareva EA, Turovaya AY, Bogdanova YA, Apsalyamova SO, Merzlyakova SN. Physiological functions of the vascular endothelium. Basic research. 2011; 11(3): 611-617.
- 14. Chatterjee S. Endothelial Mechanotransduction, Redox Signaling and the Regulation of Vascular Inflammatory Pathways. Front Physiol. 2018; 9: 524.
- 15. Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, Peccatori J, D’Angelo A, De Cobelli F, Rovere-Querini P, Tresoldi M, Dagna L, Zangrillo A. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020; 22(2): 95-97.
- 16. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3): 105924.
- 17. Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on the epidemio-logical characteristics of novel coronavirus pneumonia (COVID-19). Chin J Epidemiol. 2020; 41.
- 18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062.
- 19. Liu W, Tao Z-W, Wang L, Yuan M-L, Liu K, Zhou L, Wei S, Deng Y, Liu J, Liu H-G, Yang M, Hu Y, Analysis of factors related to the clinical outcome in hospitalized patients with a new type of coronavirus infection. Chin Med J (Engl). 2020; 133(9): 1032-1038.
- 20. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46(5): 854-887.
- 21. Guidelines for the management of critically ill adults with coronavirus disease 2019 (COVID-19), Translated by V.S. Gorokhovsky, M.B. Kutsego, A.A. Naumenko, V.D. Hunter, I.R. Cherkashina, https://rosomed.ru/documents/rukovodstvo-po-vedeniu-kriticheski-bolnyhvzroslyh-s-koronavirusnoi-boleznu-2019-covid-19-vperevode-na-russkii-yazyk (date of the application 21.04.2020).
- 22. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017; 39: 517–528.
- 23. Chakraborty RK, Burns B. Systemic Inflammatory Response Syndrome. [Updated 2020 Apr 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547669/
- 24. Gusev EY, Chereshnev VA, Yurchenko LN. Systemic inflammation from the perspective of the theory of a typical pathological process. Cytokines and inflammation. 2007; 6(4): 9-21.
- 25. Clapp BR, Hingorani AD, Kharbanda RK, Mohamed-Ali V, Stephens JW, Vallance P, MacAllister RJ. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004; 64: 172-8.
- 26. Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 1997; 181(3): 257-66.
- 27. Schalkwijk CG, Poland DCW, van Dijk W, Kok A, Emeis JJ, Drager AM, Doni A, van Hinsbergh VWM, Stehouwer CDA. Plasma concentration of c-reactive protein is increased in type i diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999; 42: 351-7.
- 28. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020; 80(6): 607-13.
- 29. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, Gotlinger KH, Hong S, Serhan CN. Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins. J Immunol. 2005; 174: 4345-55.
- 30. Norling LV, Dalli LL, Dalli J. Resolving Inflammation by using Nutrition Therapy: Roles for Specialized Pro-Resolving Mediators. Curr Opin Clin Nutr Metab Care. 2017; 20(2): 145-152.
- 31. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LAJ, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007; 21(2): 325-332.
- 32. Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Front Immunol. 2016; 7: 160
- 33. Sansbury BE, Spite M. Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis and Vascular Biology. Circ Res. 2016; 119(1): 113-30.
- 34. Serhan CN. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J. 2017; 31(4): 1273-88.
- 35. Serhan CN, Yacoubian S, Yang R. Anti-Inflammatory and Pro-Resolving Lipid Mediators. Annu Rev Pathol. 2008; 3: 279-312.
- 36. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101– 137. DOI:10,1146/annurev.immunol.25.022106.141647.
- 37. Molfino A, Amabile MI, Monti M, Muscaritoli M. Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both? Oxid Med Cell Longev. 2017; 2017: 5987082.
- 38. Duvall MG, Levy BD. DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation, Eur J Pharmacol. 2016; 785: 144-155.
- 39. Papa ND, Pignataro F. The Role of Endothelial Progenitors in the Repair of Vascular Damage in Systemic Sclerosis. Front Immunol. 2018; 9:1383.
- 40. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem. 1997; 272(11): 6972-8.
- 41. Guilford WJ, Parkinson JF. Second-generation beta-oxidation resistant 3-oxa-lipoxin A4 analogs. Prostaglandins Leukot Essent Fatty Acids. 2005; 73(3-4): 245-50.
- 42. Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis (BLXA4), ClinicalTrials.gov Identifier: NCT02342691.
- 43. Faller S, Hoetzel A. Carbon monoxide in acute lung injury. Curr Pharm Biotechnol. 2012; 13(6): 777-86.
- 44. Shinohara M, Kibi M, Riley IR, Chiang N, Dalli J, Kraft BD, Piantadosi CA, Choi AM, Serhan CN. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. Am J Physiol Lung Cell Mol Physiol. 2014; 307(10): L746-57.
- 45. Dalli J, Kraft BD, Colas RA, Shinohara M, Fredenburgh LE, Hess DR, Chiang N, Welty-Wolf K, Choi AM, Piantadosi CA, Serhan CN. The Regulation of Proresolving Lipid Mediator Profiles in Baboon Pneumonia by Inhaled Carbon Monoxide. Am J Respir Cell Mol Biol. 2015; 53(3): 314-25.
- 46. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA, Caldicott A, Martinez-Losa M, Walker TR, Duffin R, Gray M, Crescenzi E, Martin MC, Brady HJ, Savill JS, Dransfield I, Haslett C. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med. 2006; 12(9): 1056-64.
- 47. Dalli J, Norling LV, Montero-Melendez T, Federici Canova D, Lashin H, Pavlov AM, Sukhorukov GB, Hinds CJ, Perretti M. Microparticle alpha-2-macroglobulin enhances pro-resolving responses and promotes survival in sepsis. EMBO Mol Med. 2014; 6(1): 27-42.
- 48. Njock MS, Cheng HS, Dang LT, Nazari-Jahantigh M, Lau AC, Boudreau E, Roufaiel M, Cybulsky MI, Schober A, Fish JE. Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs. Blood. 2015; 125(20): 3202-12.
- 49. Wang J, Wang BJ, Yang JC, Wang MY, Chen C, Luo GX, He WF. Research advances in the mechanism of pulmonary fibrosis induced by coronavirus disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi. 2020; 36(8): 691-7.
- 50. Zhang T, Sun LX, Feng RE. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(6): 496-502.
- 51. Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol. 2020; 153(6): 725-33.
- 52. Cho JG, Lee A, Chang W, Lee MS, Kim J. Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dys-function. Front Immunol. 2018; 9: 294.
- 53. Uddin M, Levy BD. Resolvins: natural agonists for resolution of pulmonary inflammation. Prog Lipid Res. 2011; 50(1): 75-88.
- 54. Al-Soudi A, Kaaij MH, Tas SW. Endothelial cells: From innocent bystanders to active participants in immune responses. Autoimmun Rev. 2017; 16(9): 951-62.
- 55. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011; 34(5): 637-50.
- 56. Salvador B, Arranz A, Francisco S, Córdoba L, Punzón C, Llamas MÁ, Fresno M. Modulation of endothelial function by Toll like receptors. Pharmacol Res. 2016; 108: 46-56.
- 57. Khakpour S, Wilhelmsen K, Hellman J. Vascular endothelial cell Toll-like receptor pathways in sepsis. Innate Immun. 2015; 21(8): 827-46.
- 58. Herzog C, Haun RS, Kaushal GP. Role of meprin metal-loproteinases in cytokine processing and inflammation. Cytokine. 2019; 114: 18-25.
- 59. Muller WA. Transendothelial migration: unifying principles from the endothelial perspective. Immunol Rev. 2016; 273(1): 61-75.
- 60. Reglero-Real N, Colom B, Bodkin JV, Nourshargh S. Endothelial Cell Junctional Adhesion Molecules: Role and Regulation of Expression in Inflammation. Arterioscler Thromb Vasc Biol. 2016; 36(10): 2048-57.
- 61. Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev Immunol. 2015; 15(11): 692-704.
- 62. Serhan CN. Novel Pro-Resolving Lipid Mediators in Inflammation Are Leads for Resolution Physiology, Nature. 2014; 510(7503): 92-101.
- 63. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 2015; 27(3): 200-15. Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR.
- 64. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011; 254(2): 194-200.
- 65. Neves FM, Meneses GC, Sousa NE, Menezes RR, Parahyba MC, Martins AM, Libório AB. Syndecan-1 in Acute Decompensated Heart Failure--Association With Renal Function and Mortality. Circ J. 2015; 79(7): 1511-9.
- 66. Sieve I, Münster-Kühnel AK, Hilfiker-Kleiner D. Regulation and function of endothelial glycocalyx layer in vascular diseases. Vascul Pharmacol. 2018; 100: 26-33.
- 67. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018; 100: 1-19.
- 68. Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity. 2014; 41(5): 694-707.
- 69. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990; 50(4): 537-44.
- 70. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007; 7(10): 803-15.
- 71. London NR, Zhu W, Bozza FA, Smith MC, Greif DM, Sorensen LK, Chen L, Kaminoh Y, Chan AC, Passi SF, Day CW, Barnard DL, Zimmerman GA, Krasnow MA, Li DY. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med. 2010; 2(23): 23ra19.
- 72. Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020; 190: 62.
- 73. Hunt B, Retter A, McClintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19.
- 74. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020; 189(5): 846-847.
- 75. Spyropoulos AC, Ageno W, Barnathan ES. Hospital-based use of thromboprophylaxis in patients with COVID-19. Lancet. 2020; 395(10234): e75.
- 76. Fan H, Goodwin AJ, Chang E, Zingarelli B, Borg K, Guan S, Halushka PV, Cook JA. Endothelial progenitor cells and a stromal cell-derived factor-1α analogue synergistically improve survival in sepsis. Am J Respir Crit Care Med. 2014; 189(12): 1509-19.
- 77. Halaidych OV, Freund C, van den Hil F, Salvatori DCF, Riminucci M, Mummery CL, Orlova VV. Inflammatory Responses and Barrier Function of Endothelial Cells Derived from Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2018 May 8;10(5):1642-56.
- 78. Votrin SV, Vorobyev SI, Bolevich SB, Use of perfluorocarbon based blod substitute perftoran in correction of hypoxia dyring acute anemia in animals. Ser J Exp Clin Res. 2019; 20(3): 245-50.
- 79. Vorobyov SI, Moiseenko OM, Belyaev BL, Srednyakov VA, Luzganov YuV. Colloid-chemical and medico-biological characteristics of the perfluorocarbon Ftoremulsion III. Pharm Chem J. 2009; 43(5): 267-73.
- 80. Vorobyov SI. Perfluorocarbon blood-replacing emulsions of the 1st and 2nd generation. Pharm Chem J. 2009; 43(4): 30-40.